Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating triple-negative breast cancer, comprising an oligonucleotide as an active ingredient.

Abstract: An oligonucleotide variant according to an embodiment of the present disclosure has a structure of Formula 1 may exhibit excellent in-vivo stability and anticancer effects: (N)x-[TGG]m[TTG][TGG]n-(M)y??[Formula 1] wherein, N and M are independently deoxyuridine (dU), deoxycytidine (dC), uridine (U), or cytidine (C), in which a halogen or hydroxy group is bound to 5- or 2?-position thereof; x and y are independently integers of 0 to 10 (except when x and y are simultaneously 0), n is an integer of 1 to 10; and m is an integer of 1 to 10.

Abstract: One aspect of the present disclosure relates to a pharmaceutical composition for treating triple negative breast cancer, containing, as an active ingredient, a novel non-natural nucleic acid ligand that binds to both human serum albumin (HSA) and a G12D-mutation KRAS protein. The pharmaceutical composition exhibits an excellent effect on the treatment of primary or metastatic triple negative breast cancer, which is difficult to treat. In addition, one aspect of the present disclosure relates to a novel non-natural nucleic acid ligand binding to both human serum albumin (HAS) and a G12D-mutation KRAS protein, and a use thereof. The novel nucleic acid ligand may comprise a nucleic acid sequence of SEQ ID NO: 11 (GNA6AAG6CCGGA6GGCAGC666A6GC) [wherein, the second nucleic acid N is cystidine or gemcitabine and the part represented as 6 is 5-[N-(1-naphthylmethyl) carboxamide]-2?-deoxyuridine (Nap-dU)].

Abstract: One aspect of the present disclosure relates to a novel non-natural nucleic acid ligand that binds to human serum albumin (HSA), and to uses thereof. The novel non-natural nucleic acid ligand may include the nucleic acid sequence of SEQ ID NO: 8 (CAGG6CGAGC6G6ACGCG6G6G6GACC) [wherein the moiety indicated by 6 is 5-[N-(1-naphthylmethyl)carboxamide]-2?-deoxyuridine (Nap-dU)]. Meanwhile, one aspect of the present disclosure relates to a pharmaceutical composition for treating cancer, comprising a novel non-natural nucleic acid ligand that binds to human serum albumin as an active ingredient. The pharmaceutical composition exhibits excellent effects in the treatment of cancer.

Abstract: One aspect according to the present disclosure relates to a novel nucleic acid ligand which is a new class of nucleic acid compound, the existence of which was considered impossible in the prior art. The novel nucleic acid ligand has specific binding affinity with respect to at least two different targets having three-dimensional structures, and the binding sites for the at least two targets are formed in or from a single nucleic acid ligand. The novel nucleic acid ligand according the present disclosure can simultaneously solve several problems of existing aptamers that the prior art could not solve. One aspect according to the present disclosure relates to a novel screening method for identifying the above-mentioned novel nucleic acid ligand. The novel screening method uses a step for sequentially contacting at least two different targets having three-dimensional structures to screen a novel nucleic acid ligand that was previously thought impossible.

Abstract: A composition for imaging a tumorous disease region includes a fluorescence- or radioactive isotope-labeled ERBB2 aptamer, wherein the ERBB2 aptamer labeled with a radioactive isotope or a fluorescent dye is used to image the tumorous disease region in vivo. The composition may include a labeled hybridized aptamer comprising an aptamer represented as formula 1 hybridized with a labeled-ODN represented as formula 2.

Abstract: A cancer targeted therapeutic agent includes a drug-linker-AS1411 structure. The drug may be selected from monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), cytarabine, gemcitabine, maytansine, DM1, DM4, calicheamicin and a derivative thereof, doxorubicin, duocarmycin and a derivative thereof, pyrrolobenzodiazepine (PBD), SN-38, a-amanitin, or a tubulysin analog.

Abstract: A drug delivery system includes an atelocollagen-[aptamer-drug] complex which is prepared by mixing an aptamer-drug conjugate comprised of an aptamer and a drug attached to the aptamer with an atelocollagen dispersion. The aptamer is selected from the group consisting of AS1411, CRO, and ERBB2, and the drug is selected from the group consisting of Gemcitabine, Doxorubicin, and siRNA. An anticancer composition including the drug delivery system can compensate for shortcomings of existing anticancer agents and anticancer therapies.